Lalezari I, Rahbar S, Lalezari P, Fermi G, Perutz M F
Department of Anesthesiology, Montefiore Medical Center, Bronx, NY.
Proc Natl Acad Sci U S A. 1988 Aug;85(16):6117-21. doi: 10.1073/pnas.85.16.6117.
2-[4-(3,4-Dichlorophenylureido)phenoxy]-2-methylpropionic acid, LR16, combines with two symmetrically related sites in the central cavity of deoxyhemoglobin, 20 A away from the binding site of 2,3-bisphosphoglycerate, and acts as an allosteric effector synergistic with 2,3-bisphosphoglycerate. LR16 (1 mM) raises P50, the partial pressure of oxygen needed to achieve half-saturation with oxygen of a hemolysate of human hemoglobin, about 50 times more strongly than 1 mM 2,3-bisphosphoglycerate. Oral administration of LR16 (at small doses that produced no ill effects) to rats that were fed a diet rich in cholesterol caused substantial reductions of total serum cholesterol and low density lipoprotein-cholesterol, while high density lipoprotein-cholesterol remained unchanged.
2-[4-(3,4-二氯苯脲基)苯氧基]-2-甲基丙酸,LR16,与脱氧血红蛋白中央腔中的两个对称相关位点结合,该位点距2,3-二磷酸甘油酸的结合位点20埃,并作为与2,3-二磷酸甘油酸协同的变构效应剂。LR16(1 mM)提高P50,即人血红蛋白溶血产物与氧气达到半饱和所需的氧气分压,其作用强度比1 mM 2,3-二磷酸甘油酸强约50倍。给喂食富含胆固醇饮食的大鼠口服LR16(小剂量且无不良影响)可使总血清胆固醇和低密度脂蛋白胆固醇大幅降低,而高密度脂蛋白胆固醇保持不变。